Thursday, July 25, 2013
The seemingly intractable nature of neuropathic pain has led
drug developers to look beyond classical receptor and transporter protein
targets and explore the emerging field of epigenetics to find new options. Now,
researchers at The Johns
Hopkins University School of Medicine have found a
potential target based on the discovery that nerve injury upregulates a long noncoding
RNA that silences voltage-gated potassium
channel Kv1.2 exclusively in damaged neurons.1
Fishburn, C.S. SciBX 6(28); doi:10.1038/scibx.2013.711
Published online July 25, 2013
1. Zhao, X. et al. Nat.
Neurosci.; published online June 23, 2013; doi:10.1038/nn.3438
Contact: Yuan-Xiang Tao, The Johns Hopkins University School of
Medicine, Baltimore, Md.
2. Qureshi, I.A. et al.
Brain Res. 1388, 20-35 (2010)
3. Singh, O.V. et al.
Proteomics 9, 1241-1253 (2009)
4. Brew, H.M. et al. J.
Neurophysiol. 98, 1501-1525 (2007)
5. Butler, M. et al.
Lab Invest. 77, 379-388 (1997)
6. Rigo, F. et al. J.
Cell Biol. 199, 21-25 (2012)
7. Kabanov, A.V. Adv.
Drug Deliv. Rev. 58, 1597-1621 (2006)
Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland
Johns Hopkins University School of Medicine, Baltimore, Md.
Opko Health Inc. (NYSE:OPK), Miami, Fla.
RaNA Therapeutics Inc., Cambridge, Mass.
TransSINE Technologies Co. Ltd., Yokohama, Japan
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), Cambridge, Mass.
Xenon Pharmaceuticals Inc., Burnaby, British Columbia, Canada